Finn
JAZZ Biopharma · Rare disease · Neuroscience · Oncology · Thesis updated November 8, 2026

Ziihera adds oncology growth as Xywav defends its patient base

01 Running thesis

The Xyrem handoff is working

Jazz is trying to move past its old Xyrem franchise without losing the cash it needs to fund the next chapter. The transition is showing clear signs of success. Xywav, its lower-sodium oxybate drug, reached 17,550 active patients in Q3 2026, even with new high-sodium generics available.

The bull case is that Jazz can keep most valuable sleep patients on Xywav while Epidiolex keeps growing and oncology becomes a larger second engine. Zepzelca now has a strong first-line maintenance role in small cell lung cancer, though its second-line label was removed. Ziihera launched strongly in first-line gastroesophageal adenocarcinoma, capturing over 80 percent of new accounts in community settings.

The bear case centers on how the sleep market could change. High-sodium generics might gain more volume over time. New orexin 2 receptor agonists could delay Xywav patient starts. If payers use cheaper choices to pressure Xywav, Jazz could lose price or patient share. In oncology, Zepzelca faces expected competition in 2027.

Finn scores the company well on performance, as the business is executing on its pipeline. Jazz must continue defending Xywav, growing Epidiolex, and proving the oncology pipeline can offset any sleep franchise weakness.

Nov 2026▲Q3 2026 results established Ziihera as a key growth pillar with a strong launch. Xywav demonstrated significant resilience, while Zepzelca's outlook faced pressure from competition.
Aug 2026▲Q2 2026 results showed Xywav resilience with 525 net patient additions. Zepzelca also gained significant traction in first-line maintenance, supported by an NCCN category 1 listing.
May 2026▲Q1 2026 showed better near-term Xywav resilience than feared, with 425 net patient adds. Jazz also confirmed an August 25, 2026 FDA decision date for Ziihera.
Feb 2026▼Sleep competition became a larger risk. Amneal and Ascent had approvals for generic high-sodium oxybate, and Alkermes bought Avadel.
Feb 2026→Epidiolex reached $1.1 billion of 2025 revenue, and Jazz settled litigation that moved generic risk into the very late 2030s.
Nov 2025▲Jazz cleared several overhangs and added oncology momentum. Modeyso was approved in August 2025, and Zepzelca gained first-line maintenance approval.
Aug 2025▼Macro reimbursement risk increased after H.R.1 was signed into law. Jazz warned that lower Medicaid spending could reduce access for its products.
02 Business model

Rare drugs, concentrated markets

Jazz makes money by selling branded medicines for rare or hard-to-treat diseases. These are not mass-market drugs. They are aimed at specific groups of doctors and patients. This makes the sales model efficient when the drug has a strong label and good insurance coverage.

Sleep remains the biggest source of product sales. In Q3 2026, Xywav net sales reached $483 million. Xywav has 92 percent less sodium than Xyrem, which gives Jazz a clear medical message against high-sodium oxybate drugs.

Epilepsy adds a more durable base. Epidiolex generated $295 million in Q3 2026. Settlements moved expected U.S. generic entry into the very late 2030s, giving Jazz more time to grow the product. The company also added ABS-1230 for rare epilepsy through its acquisition of Actio Biosciences.

Oncology is the fastest growing division. Zepzelca reached $104 million in Q3 2026. Cancer drugs can rise or fall quickly based on trial data and FDA decisions, making pipeline execution essential.

03 Product portfolio

The drugs that drive the story

Cash cow

Xywav

Xywav is the key sleep drug and the main bridge away from Xyrem. It had $483 million in Q3 2026 sales and 17,550 active patients.

Growth engine

Epidiolex

This cannabidiol medicine treats seizures tied to rare epilepsies. It generated $295 million in Q3 2026.

Growth engine

Zepzelca

Zepzelca treats small cell lung cancer. Q3 2026 sales were $104 million, driven by adoption in first-line maintenance.

Steady

Rylaze

Rylaze is used in certain leukemia and lymphoma patients who cannot use older asparaginase products.

Growth engine

Ziihera

Ziihera is a targeted cancer drug that recently launched in first-line gastroesophageal adenocarcinoma.

Option

Modeyso

Modeyso treats a rare brain tumor. A major overall survival readout from the ACTION trial is expected in early 2027.

04 Business segments

Sales mix

Sleep40%modest
Epilepsy25%modest
Oncology34%growing fast
Other product sales1%declining

The mix reflects estimated trends exiting Q3 2026. Sleep is still the largest area, making it critical to the company valuation.

05 Risk factors

What could break the thesis

Xywav payer pressure and competition

High impact · High odds

Amneal and Ascent began dispensing generic high-sodium oxybate products in 2026. Furthermore, new orexin 2 receptor agonists could delay Xywav patient starts. Cheaper generics and new branded rivals can push insurers to demand larger rebates.

We watchTrack Xywav active patients, Xywav net sales growth, and management comments on formulary access.

Xywav patent challenge

High impact · Medium odds

In January 2026, Tris Pharma filed an application that references both Xyrem and Xywav. That creates a direct legal risk for the newer low-sodium franchise. A bad ruling could pull forward generic competition for Xywav.

We watchFollow the Tris litigation docket and any settlement terms tied to Xywav entry timing.

Oncology competition

Medium impact · High odds

Jazz needs oncology to become a bigger growth engine. Zepzelca lost its second-line label and faces major 2027 competition in first-line maintenance from Imdelltra. If Ziihera sales stall or trials disappoint, diversification slows.

We watchWatch Zepzelca revenue trends, Ziihera launch metrics, and the Modeyso ACTION overall survival readout.

Government drug pricing pressure

Medium impact · Medium odds

U.S. health policy is becoming less friendly for drug makers. Changes to Medicare and Medicaid policies could reduce reimbursement. Rylaze and Epidiolex have higher government exposure, making them more sensitive to this risk.

We watchMonitor Medicaid access changes, Medicare pricing rules, and Jazz commentary on gross-to-net deductions.
06 Quick answers

In one breath

What does Jazz Pharmaceuticals make?

Jazz sells medicines for sleep disorders, rare epilepsies, and cancers. Its most important drugs include Xywav, Epidiolex, Rylaze, Zepzelca, Ziihera, and Modeyso.

Why is Xywav so important to Jazz?

Xywav is the lower-sodium follow-on to Xyrem and is Jazz's biggest product. It had $483 million of Q3 2026 product sales, so its patient count and insurance access are central to the stock story.

What is the next big catalyst for Jazz?

Jazz expects top-line overall survival data from the Modeyso ACTION trial in the first half of 2027, as well as initial data from ABS-1230 in late 2026.

Is Jazz mainly a sleep company or an oncology company?

Today it is still heavily tied to sleep, but oncology is growing faster and adding key new products like Ziihera. Both segments contribute heavily to total revenue.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 8, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Jazz Pharmaceuticals Q3 2026 earnings transcript
  2. Jazz Pharmaceuticals Q2 2026 Form 10-Q
  3. Jazz Pharmaceuticals 2025 Form 10-K
08 Explore the industry

Comparable Biotechnology companies

Companies near Jazz Pharmaceuticals plc in Finn's Biotechnology industry ranking.

Get started with Finn today